Guillermo Garcia-Manero, MD
Medical Oncology · Houston, TXNPI 1013078294
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $297,634 of the $453,601 with a category attached, or 65.6%. It is spread thinly across 34 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2024 at $93,048 and has fallen 50.3% since, to $46,274 in 2025. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $1737.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$94K
- E.r. Squibb & Sons, L.L.C.$72K
- Novartis$48K
- Taiho Oncology, Inc.$34K
- Dr.reddy's Laboratories,inc.$24K
- Hikma Pharmaceuticals USA$24K
- plus $156K from 28 others
Across 761 payments — averaging $40,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$18.2M
- Otsuka Pharmaceutical Co., Ltd.$3.1M
- Merck$2.8M
- Rigel Pharmaceuticals, Inc.$2.3M
- Taiho Oncology, Inc.$1.7M
- AbbVie$765K
- plus $2.2M from 12 others
What the payments were for
- Consulting fees$297,63466%
- Speaking & faculty fees$46,85810%
- Travel & lodging$88,70620%
- Food & beverage$7,1222%
- Education$13,2803%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 65 | $94,381 |
| E.r. Squibb & Sons, L.L.C. | 30 | $72,368 |
| Novartis | 17 | $48,287 |
| Taiho Oncology, Inc. | 29 | $34,153 |
| Dr.reddy's Laboratories,inc. | 8 | $24,350 |
| Hikma Pharmaceuticals USA | 9 | $23,566 |
| GSK | 12 | $18,300 |
| Geron Corporation | 13 | $16,316 |
| AbbVie | 13 | $12,735 |
| Gilead | 9 | $12,635 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $12,606 |
| Otsuka Pharmaceutical Co., Ltd. | 3 | $11,912 |
| Sumitomo Pharma America, Inc. | 2 | $11,424 |
| Helsinn Healthcare SA | 5 | $10,080 |
| Servier Pharmaceuticals LLC | 5 | $7,461 |
| Ipsen Biopharmaceuticals, Inc | 2 | $6,200 |
| Chiesi USA, Inc. | 1 | $4,785 |
| Amgen | 2 | $4,760 |
| Regeneron | 4 | $3,378 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $3,300 |
| Acceleron Pharma, Inc. | 1 | $3,000 |
| Janssen Global Services, LLC | 4 | $2,924 |
| Daiichi Sankyo Inc. | 1 | $2,903 |
| Merck | 1 | $2,440 |
| Genentech, Inc. | 1 | $2,145 |
| Astrazeneca UK Limited | 1 | $1,556 |
| Tempus AI, Inc | 1 | $1,500 |
| Seagen Inc. | 3 | $1,451 |
| AstraZeneca | 5 | $1,432 |
| Ipsen Innovation | 1 | $870 |
| Genentech USA, Inc. | 2 | $227 |
| Astellas Pharma US Inc | 1 | $110 |
| Sanofi-aventis U.S. LLC | 1 | $30 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INQOVI$18,235
- Reblozyl$17,920
- Oncology TA$13,426
- Azacitidine$10,700
- Decitabine$9,200
- ONUREG$8,878
- IMETELSTAT$8,865
- TIBSOVO$7,461
- RYTELO$7,164
- Venclexta$6,552
- IDHIFA$5,288
- FERRIPROX$4,785
- Kyprolis$4,760
- Lonsurf$4,435
- Revlimid$3,966
- Non-Covered Product$2,145
- XOSPATA$110
How this compares
$453,601 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 40 | $41,885 |
| ValacyclovirValacyclovir Hcl | 15 | $361 |
| Levofloxacin | 12 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $12,735 | $41,88540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Jason WestinHouston$407K
- Eric JonaschHouston$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.